Your browser doesn't support javascript.
loading
NEDA treatment target? No evident disease activity as an actionable outcome in practice.
Parks, Natalie E; Flanagan, Eoin P; Lucchinetti, Claudia F; Wingerchuk, Dean M.
Afiliação
  • Parks NE; Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA; Division of Neurology, Dalhousie University, 1341 Summer Street, Halifax, NS B3H4K4, Canada. Electronic address: nparks@dal.ca.
  • Flanagan EP; Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Electronic address: flanagan.eoin@mayo.edu.
  • Lucchinetti CF; Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Electronic address: clucchinetti@mayo.edu.
  • Wingerchuk DM; Department of Neurology, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA. Electronic address: wingerchuk.dean@mayo.edu.
J Neurol Sci ; 383: 31-34, 2017 Dec 15.
Article em En | MEDLINE | ID: mdl-29246616
"No evident disease activity" (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Intervalo Livre de Doença / Esclerose Múltipla Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Revista: J Neurol Sci Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Intervalo Livre de Doença / Esclerose Múltipla Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Revista: J Neurol Sci Ano de publicação: 2017 Tipo de documento: Article